Eli Lilly's Zepbound Facing Supply Shortage in U.S.

Chronic Shortage of Zepbound by Eli Lilly

Eli Lilly's weight-loss drug Zepbound, known by its generic name tirzepatide, has been struggling with a severe supply shortage in the United States. The increasing demand for this medication has resulted in challenges for patients and healthcare professionals reliant on its availability.

Impact on Patients and Healthcare Providers

The scarcity of Zepbound until the end of April presents a critical issue for individuals seeking weight-loss treatments and healthcare providers managing patients requiring such medications. The limited availability raises concerns about the impact on the health and well-being of those requiring this pharmaceutical intervention.